ADVERTISEMENT
News
Ulcerative Colitis Drug Recalled
03/13/2020
The recall affects 120-count bottles of mesalamine delayed-release tablets, 1.2 grams (NDC 0591-2245-22), from lot 1342500A (Exp. 10/20).
Teva Pharmaceuticals voluntarily initiated the recall February 20, 2020. On March 2, 2020, the FDA designated the recall Class II. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.
Mesalamine is a prescription nonsteroidal anti-inflammatory drug used to treat ulcerative colitis and to prevent ulcerative colitis flare-ups.
—Jolynn Tumolo